29609532Atallah E, Schiffer CA, Weinfurt KP, Zhang MJ, Radich JP, Oehler VG, Pinilla-Ibarz J, Deininger MWN, Lin L, Larson RA, Mauro MJ, Moore JO, Ritchie EK, Shah NP, Silver RT, Wadleigh M, Cortes J, Thompson J, Guhl J, Horowitz MM, Flynn KEBMC cancerClinical Protocols; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Quality of Life; Watchful WaitingAntineoplastic Agents; Fusion Proteins, bcr-abl; Humans; Longitudinal Studies; Molecular Targeted Therapy; Patient Reported Outcome Measures; Protein Kinase Inhibitors; Recurrence; Research DesignDesign and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. BMC Cancer. 2018 04 02; 18(1):359.BMC Cancer2018-04-02T00:00:002018Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.prns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:hasSubjectAreaMajorTopicListhas major subject area listprns:hasSubjectAreaMinorTopicListhas minor subject area listprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed Identifiervivo:authorRankauthor rank in publicationAuthorshipDepartmentvivo:hasSubjectAreahas subject areavivo:hrJobTitleHR job titleInformation Resourcevivo:informationResourceInAuthorshipauthorsvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonD000970Chemicals & Drugs40723510.435494Antineoplastic AgentsD002985Procedures1151550.937211Clinical ProtocolsAuthorship 115123100.1650480.1650481authors10.2513has subject areaD012008Phenomena39011370.784621RecurrenceD011788Concepts & Ideas43115750.549294Quality of LifeD006801Living Beings2262862810.130064HumansMedicine-Hematology and OncologyD057832Concepts & Ideas31600.937908Watchful WaitingD012107Concepts & IdeasLiving BeingsProcedures2505940.748878Research DesignD058990Procedures1352660.83112Molecular Targeted TherapyD016044Chemicals & Drugs271070.945506Fusion Proteins, bcr-ablD0000710661041650.893853Patient Reported Outcome MeasuresD008137Concepts & IdeasProcedures36010150.76021Longitudinal StudiesD015464Disorders401730.88613Leukemia, Myelogenous, Chronic, BCR-ABL PositiveD047428Chemicals & Drugs2065890.714226Protein Kinase InhibitorsUniversity of ChicagoRichard A.LarsonRichard A. Larson41.78927490000000-87.601250000000001169Larson, Richard A.Professortrue1ProfessorProfessor